Your browser doesn't support javascript.
loading
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka, Keiko; Itagaki, Kanako; Hashiya, Nozumu; Wakugawa, Sorako; Tanaka, Koji; Nakayama, Makiko; Yamamoto, Akiko; Mukai, Ryo; Honjyo, Jyunichiro; Maruko, Ichiro; Kawai, Moeko; Miyara, Yasunori; Terao, Nobuhiro; Wakatsuki, Yu; Onoe, Hajime; Mori, Ryusaburo; Koizumi, Hideki; Sekiryu, Tetsuju; Iida, Tomohiro; Okada, Annabelle A.
Afiliación
  • Kataoka K; Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan. keiko-kataoka@ks.kyorin-u.ac.jp.
  • Itagaki K; Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
  • Hashiya N; Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
  • Wakugawa S; Department of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
  • Tanaka K; Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
  • Nakayama M; Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
  • Yamamoto A; Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
  • Mukai R; Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
  • Honjyo J; Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
  • Maruko I; Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
  • Kawai M; Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
  • Miyara Y; Department of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
  • Terao N; Department of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
  • Wakatsuki Y; Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
  • Onoe H; Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
  • Mori R; Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.
  • Koizumi H; Department of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
  • Sekiryu T; Department of Ophthalmology, Fukushima Medical University, Fukushima, Japan.
  • Iida T; Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan.
  • Okada AA; Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, Japan.
Graefes Arch Clin Exp Ophthalmol ; 262(1): 43-51, 2024 Jan.
Article en En | MEDLINE | ID: mdl-37668741
PURPOSE: To assess 6-month outcomes of switching from aflibercept to faricimab in eyes with refractory neovascular age-related macular degeneration (nAMD) previously requiring monthly injections. METHODS: This multicenter retrospective study examined nAMD eyes receiving monthly aflibercept injections switched to faricimab administered monthly up to 4 injections followed by injections at a minimum of 2-month intervals as per drug labeling. Data regarding age, sex, number of previous injections, treatment intervals, and best-corrected visual acuity (BCVA) were collected. Central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), and maximal pigment epithelial detachment (PED) height were measured by optical coherence tomography. RESULTS: The study included 130 eyes of 124 patients. At 6 months, 53 eyes (40.8%) continued on faricimab treatment (Group 1), while 77 eyes (59.2%) discontinued faricimab for various reasons (Group 2) the most common being worse exudation. There were no significant differences between the two groups at baseline. In Group 1, CRT and SFCT significantly decreased at 1 month (P = 0.013 and 0.008), although statistical significance was lost at 6 months (P = 0.689 and 0.052). BCVA and maximal PED height showed no significant changes; however, mean treatment intervals were extended from 4.4 ± 0.5 weeks at baseline to 8.7 ± 1.7 weeks at 6 months (P < 0.001) in Group 1. No clear predictors of response were identified. CONCLUSION: Switching from aflibercept to faricimab allowed for extension of treatment intervals from monthly to bimonthly in roughly 40% of eyes, suggesting that faricimab may be considered in refractory nAMD cases.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Desprendimiento de Retina / Anticuerpos Biespecíficos / Degeneración Macular Húmeda / Degeneración Macular Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Graefes Arch Clin Exp Ophthalmol Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Desprendimiento de Retina / Anticuerpos Biespecíficos / Degeneración Macular Húmeda / Degeneración Macular Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Graefes Arch Clin Exp Ophthalmol Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Alemania